Comparative Pharmacology
Head-to-head clinical analysis: MIRALAX versus SUTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRALAX versus SUTAB.
MIRALAX vs SUTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polyethylene glycol 3350 (PEG 3350) is an osmotic laxative that works by retaining water in the stool through hydrogen bonding, increasing fecal water content and promoting bowel movements.
SUTAB is a combination tablet consisting of sodium sulfate, magnesium sulfate, and potassium chloride. It acts as an osmotic laxative by drawing water into the bowel lumen through the osmotic effect of sulfate ions, inducing colonic evacuation. Additionally, magnesium ions enhance this effect by attracting water via osmotic pressure and stimulating the release of cholecystokinin, which promotes peristalsis.
17 g (1 heaping tablespoon) dissolved in 4–8 oz of water, juice, soda, coffee, or tea, administered orally once daily. Maximum duration of use: 7 days.
24 tablets administered as 4 tablets every 15 minutes, total dose of 17.5 g sodium sulfate, 3.13 g magnesium sulfate, and 1.64 g potassium sulfate, orally, with water, the evening before colonoscopy.
None Documented
None Documented
Not applicable; polyethylene glycol 3350 is minimally absorbed and systemic half-life is not clinically relevant.
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 20-40 hours in end-stage renal disease.
Primarily excreted unchanged in feces (>90% of oral dose); negligible renal elimination (<0.1% recovered in urine).
Primarily renal excretion (65-75% unchanged) with minor biliary/fecal elimination (<10%). Total body clearance approximates renal blood flow.
Category C
Category C
Osmotic Laxative
Osmotic Laxative